全文获取类型
| 收费全文 | 33444篇 |
| 免费 | 2362篇 |
| 国内免费 | 275篇 |
专业分类
| 耳鼻咽喉 | 493篇 |
| 儿科学 | 606篇 |
| 妇产科学 | 730篇 |
| 基础医学 | 4705篇 |
| 口腔科学 | 877篇 |
| 临床医学 | 3102篇 |
| 内科学 | 6496篇 |
| 皮肤病学 | 663篇 |
| 神经病学 | 2373篇 |
| 特种医学 | 1828篇 |
| 外科学 | 5227篇 |
| 综合类 | 450篇 |
| 一般理论 | 10篇 |
| 预防医学 | 1529篇 |
| 眼科学 | 763篇 |
| 药学 | 2903篇 |
| 1篇 | |
| 中国医学 | 286篇 |
| 肿瘤学 | 3039篇 |
出版年
| 2023年 | 159篇 |
| 2022年 | 324篇 |
| 2021年 | 855篇 |
| 2020年 | 464篇 |
| 2019年 | 781篇 |
| 2018年 | 865篇 |
| 2017年 | 686篇 |
| 2016年 | 809篇 |
| 2015年 | 1136篇 |
| 2014年 | 1439篇 |
| 2013年 | 1705篇 |
| 2012年 | 2541篇 |
| 2011年 | 2489篇 |
| 2010年 | 1521篇 |
| 2009年 | 1372篇 |
| 2008年 | 1972篇 |
| 2007年 | 1955篇 |
| 2006年 | 1822篇 |
| 2005年 | 1720篇 |
| 2004年 | 1569篇 |
| 2003年 | 1398篇 |
| 2002年 | 1239篇 |
| 2001年 | 1037篇 |
| 2000年 | 1001篇 |
| 1999年 | 788篇 |
| 1998年 | 289篇 |
| 1997年 | 258篇 |
| 1996年 | 239篇 |
| 1995年 | 201篇 |
| 1994年 | 172篇 |
| 1993年 | 145篇 |
| 1992年 | 364篇 |
| 1991年 | 270篇 |
| 1990年 | 284篇 |
| 1989年 | 264篇 |
| 1988年 | 230篇 |
| 1987年 | 179篇 |
| 1986年 | 161篇 |
| 1985年 | 130篇 |
| 1984年 | 122篇 |
| 1983年 | 99篇 |
| 1982年 | 78篇 |
| 1981年 | 72篇 |
| 1980年 | 64篇 |
| 1979年 | 96篇 |
| 1978年 | 76篇 |
| 1977年 | 67篇 |
| 1974年 | 67篇 |
| 1972年 | 59篇 |
| 1971年 | 65篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
2.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study 
下载免费PDF全文
下载免费PDF全文 3.
4.
5.
6.
7.
Ngai-Yin Chan Chi-Chung Choy Ho-Chuen Yuen Hoi-Fan Chow Ho-Fai Fong 《The Canadian journal of cardiology》2019,35(4):396-404
Background
Persistent iatrogenic atrial septal defect (iASD) is a common but poorly characterized complication after cryoballoon (CB) pulmonary vein isolation (PVI) procedures. We therefore investigate its prevalence, evolution, risk factors, and clinical outcomes in a prospective longitudinal study.Methods
A total of 108 patients (41 women, mean age 57 ± 11.3) underwent CB PVI for AF. Serial transesophageal echocardiography (TEE) was performed 9 months and then annually until 6 years after the procedure to study the characteristics of persistent iASD.Results
Persistent iASD occurred in 33 (30.6%) patients 9 months after CB PVI. Spontaneous closure of iASD was found in 6 (22.2%) and 3 (15.8%) patients 2 and 3 years after the procedures, respectively. No spontaneous closure was observed on 4, 5, and 6-year TEE follow-up. The projected long-term persistence rate of iASD after CB PVI was therefore 20% (30.6% × 0.778 × 0.842). Using multivariate logistic regression, a higher number of cryoapplications (≥ 2 minutes) was the only independent predictor of persistent iASD 9 months after CB PVI (odds ratio [OR] 1.207; 95% confidence interval [CI], 1.033-1.411, P = 0.018). Two (1.9%) patients with significantly larger iASD size than the others (long diameter 12.6 ± 0.8 vs 3.7 ± 1.5 mm, P < 0.001; short diameter 10.9 ± 0.2 vs 3 ± 1.1 mm, P < 0.001) required percutaneous closure because of exertional dyspnea and right ventricular enlargement. Over 129.7 patient-years follow-up, during which iASD persisted, there was no occurrence of neurologic events.Conclusions
Approximately one fifth of patients undergoing CB PVI will have permanently persistent iASD. Patients with defect sizes of greater than 10 mm may need percutaneous closure due to significant left-to-right shunting. 相似文献8.
9.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
下载免费PDF全文 10.
Miju Bae Sung Woon Chung Chung Won Lee Up Huh Min Su Kim Seung Hwan Song 《Asian journal of surgery / Asian Surgical Association》2019,42(1):235-239